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Abstract
Background: Intermittent androgendeprivation (IAD) has received increasing attention; however, the
current literature is still limited, especially in nonmetastatic prostate cancer (PCa), and the relative
efficacy and safety benefits of IAD versus continuous androgen deprivation (CAD) remain unclear.
Objective: To add to the knowledge base regarding efﬁcacy and potential beneﬁts, including reduced
side effects and improved quality of life (QoL), of IAD versus CAD in patients with nonmetastatic
relapsing or locally advanced PCa.
Design, setting, and participants: A 42-mo phase 3b open-label randomised study in 933 patients
from 20 European countries.
Intervention: Following a 6-mo induction with leuprorelin acetate (Eligard) 22.5 mg 3-mo depot,
patients were randomised to CAD or IAD with leuprorelin for 36 mo.
Outcome measurements and statistical analysis: The primary endpointwas time to prostate-speciﬁc
antigen (PSA) progression while receiving luteinising hormone-releasing hormone agonist, deﬁned as
three consecutive increasing PSA values 4 ng/ml 2 wk apart. Secondary end points included PSA
progression-free survival (PFS), overall survival (OS), testosterone levels, performance status, andQoL.
Results and limitations: A total of 933 patients entered the induction phase; 701 were randomised.
The median number of injections administered after randomisation was 12 (range: 112) for the
CAD group and 3 (range: 1–10) for the IAD group. There were no statistically signiﬁcant or clinically
relevant differences between the groups for time to PSA progression, PSA PFS, OS, mean PSA levels
ilar number of adverse events was observed in each group; themost common
pertension. Study limitations include the open-label design and absence ofNonmetastatic
Prostate-specific antigen
over time, or QoL. A sim
were hot ﬂushes and hyprogression formal testosterone recovery assessment.
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Patient summary: This randomised trial showed that both intermittent and continuous hormone
therapy had similar efﬁcacy, tolerability, and quality-of-life proﬁles in patients with relapsing M0 or
locally advanced prostate cancer. Intermittent therapy may be a valid option for selected patients.
Trial registration: ClinicalTrials.gov identiﬁer NCT00378690.
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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It has long been recognised that continuous androgen
deprivation (CAD) therapy in patients with prostate cancer
(PCa) can induce side effects such as decreased libido,
impotence, decreased lean body mass, increased fat mass,
increased insulin resistance, and osteoporosis [1]. These
effects cansignificantlyalterqualityof life (QoL), especially in
younger men. One alternative approach to CAD, recom-
mended by the European Association of Urology (EAU) [2]
andtheNational Institute ofHealthandCareExcellence [3], is
intermittent androgen deprivation (IAD) therapy, during
which androgen deprivation therapy (ADT) is discontinued
once prostate-specific antigen (PSA) levels fall below a
certain level and is restarted when PSA levels begin to rise
[4]. The 2015 EAU guidelines suggest that IAD can be offered
to a range of patientswith PCa after a standardised induction
period of ADT [2], providing they are willing and able to
comply with the strict follow-up (and clinical examinations)
necessitated by this treatment approach.
Although the concept of IAD is not new [5], the literature
still largely fails to answer the question of the relative
benefits of IAD versus CAD, especially in nonmetastatic
patients. Recent studies conclude that IAD is noninferior to
CAD in terms of overall survival (OS), although one study in
patients with metastatic disease showed small OS benefits
with IAD [6] and was equivalent to CAD for cancer control.
Findings are less clear regarding prevention of long-term
effects of ADT and QoL outcomes [4,7–9]; however, previous
studies were heterogeneous in design, study populations,
and treatment schedules.
As such, the ICELAND study, conducted in 20 European
countries, aimed to add to the knowledge base regarding
the efficacy and safety profile of IAD compared with CAD,
focusing on a nonmetastatic population treated with the
luteinising hormone-releasing hormone (LHRH) analogue
leuprorelin acetate 3-mo depot, which has not been widely
evaluated in the context of IAD.
2. Patients and methods
2.1. Design and procedures
This was a 42-mo phase 3b open-label randomised multicentre study,
recruiting patients from 102 centres in 20 European countries
(Supplementary Table 1). Men with locally advanced PCa (T3T4)
or elevated or rising PSA levels (5 mg/ml) after radical prostatectomy
(RP) or radiotherapy were screened. Inclusion criteria were age 18
and <80 yr, Gleason score 6, Eastern Cooperative Oncology Group
(ECOG) performance status score 0–2, and 5-yr life expectancy.
Patients were excluded if they had any other malignancy or metastatic
disease, were receiving chemotherapy or other hormonal therapy, had
testosterone levels 1.7 nmol/l or 50 ng/dl, or had any condition that
would preclude safe study completion. Patients underwent a rigorous
assessment at screening, including TNM classiﬁcation and a biopsy-
based Gleason assessment. Radionuclide bone scan (technetium 99m-
methylene diphosphonate bone scintigraphy) or a computed tomog-
raphy scan of the abdomen and pelvis was also performed to exclude
the presence of metastases. Patients provided written informed
consent prior to study entry. The protocol was reviewed by theindependent ethics committee/institutional review board at each
study centre.
2.1.1. Treatment
The induction treatment phase ran from screening (visit 1) to
randomisation (visit 4). Patients were treated with leuprorelin acetate
(Eligard; Astellas Pharma Inc [1_TD$DIFF]., Northbrook, IL, USA) 22.5 mg 3-mo depot
for 6 mo and received bicalutamide (Casodex; AstraZenica, London, UK)
50 mg once daily for 1 mo from the ﬁrst injection. PSA determinations
were made up to 2 wk before each visit so the result was available to the
investigator at the visit. Two successive PSA levels 1 ng/ml (2 wk
apart) after 6mowere required for patients to proceed to randomisation.
The randomised phase ran from visit 4 (month 6) to visit 16
(month 42). Patients were randomly assigned to either CAD or IAD with
leuprorelin acetate 22.5 mg 3-mo depot. Patients randomised to IAD had
ADT discontinued immediately after randomisation and entered the ﬁrst
off-treatment phase. If the patient’s serum PSA level rose to 2.5 ng/ml,
independent of testosterone level, treatment was restarted every 3 mo
(plus bicalutamide 50 mg for 1 mo) until PSA declined to 1 ng/ml (on
two successive occasions 2 wk apart). Both CAD and IAD were stopped
36 mo after randomisation, and patient follow-up was at 6-mo intervals
for 18 mo. Study visit timing is outlined in Supplementary Figure 1. The
ﬁrst patient’s ﬁrst visit was in March 2006; the ﬁnal patient’s last visit
was in April 2013.
2.1.2. Primary end point
The primary end point was time to PSA progression, deﬁned as three
consecutive increasing PSA values 4 ng/ml at least 2 wk apart while
receiving leuprorelin.
2.1.3. Secondary end points
Secondary efﬁcacy end points included PSA progression-free survival
(PFS), deﬁned as time from randomisation to either PSA progression or
death; OS, deﬁned as time from randomisation to either the last available
assessment or death, occurring no later than 60mo after randomisation;
time to serum testosterone >50 ng/dl or 1.7 nmol/l (CAD group only);
World Health Organization (WHO)/ECOG performance status (5-point
scale); and health-related QoL, measured by EORTC QLQ-C30 and
PCa-speciﬁc module QLQ-PR25.
Testosterone levels and testosterone breakthrough (deﬁned as
time to serum testosterone >50 ng/dl or 1.7 nmol/l [conventional] or
>20 ng/dl or 0.7 nmol/l [conservative]) were assessed at each visit.
EORTC QLQ-C30 and QLQ-PR25 questionnaires [10,11] were completed
at visits 2–16 and at early withdrawal.
2.1.4. Safety
Reported adverse events (AEs) were graded according to the National
Cancer Institute Common Terminology Criteria for Adverse Events, v.3.0.
2.1.5. Power calculations and statistical analyses
With 350 randomised patients per arm, it was calculated that the study
would provide 90% power to demonstrate superiority on the primary
end point at the ﬁnal analysis (3 yr after randomisation) if the proportion
of patients with PSA progression at 3 yr was 38.9% in the CAD arm, based
on previous estimates [12], and <27.3% or >51.2% in the IAD arm.
Efﬁcacy, safety, and tolerability data were analysed for all patients
who were randomised at visit 4 and treated. Time-to-event data were
analysed using the Kaplan-Meier method.
3. Results
Of 1131 screened patients, 933 entered the induction phase
(Fig. 1). There were no relevant differences between
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Screened
n = 1131
Randomised, n = 701
CADb
Safety, n = 361
Efficacy, n = 361
IADb
Safety, n = 340
Efficacy, n = 340
CAD
Safety, n = 353
Efficacy, n = 352
IAD
Safety, n = 337
Efficacy, n = 334
Withdrawals before
follow-up (CAD)
Safety, n = 43
Efficacy, n = 43
Entering the follow-up (CAD)
Safety, n = 310
Efficacy, n = 309
Entering the follow-up (IAD)
Safety, n = 292
Efficacy, n = 290
Completing the follow-up (CAD)
Safety, n = 59
Efficacy, n = 59
Completing the follow-up (IAD)
Safety, n = 42
Efficacy, n = 42
Entered induction phase, n = 933
Analysed for safety, n = 932
Analysed for efficacy, n = 932
Not eligible
n = 198
Discontinued/not randomised, n = 232a
Not fulfilling inclusion or exclusion
criteria, n = 176 (75.9%)
Adverse event, n = 5 (2.2%)
Death, n = 6 (2.6%)
Withdrawal of consent, n = 13 (5.6%)
Subject lost to follow-up, n = 3 (1.3%)
Protocol violation, n = 5 (2.2%)
Worsening of disease, n = 2 (0.9%)
Other, n = 22 (9.5%)
Withdrawals before
follow-up (IAD)
Safety, n = 45
Efficacy, n = 44
Fig. 1 – Disposition of patients.
a There is a discrepancy in the nonrandomised group due to a patient who was not documented as a screening failure, although he should have
been, based on the fact that one of the inclusion criteria was not met (locally advanced but TNM classification was missing); no leuprolide acetate
was administered.
b Population additionally included patients who were not randomised.
CAD = continuous androgen deprivation; IAD = intermittent androgen deprivation.
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comorbidities (Table 1).
During induction, median testosterone levels for all
patients decreased from397ng/dl (13.8 nmol/l) to11.0 ng/dl
(0.4 nmol/l) at month 3, with a further small decline at
month 6. Median PSA levels decreased from 8.6 ng/ml to
0.20 ng/ml atmonth 3 and remained at this level atmonth 6.Overall, 701 patients were randomised (Fig. 1), of whom
58% had locally advanced disease, 26.7% had relapsing PCa
following RP, and 15.3% had relapsing PCa following other
therapies. A total of 131 patients (19.1%) withdrew after
randomisation: 70 in the CAD group and 61 in the IAD
group. Supplementary Table 2 details the primary reasons
for study withdrawal.
Table 1 – Baseline disease characteristics and comorbidity profile
CAD
(n = 361)
IAD
(n = 340)
Not randomised
(n = 231)
Total
(n = 932)
p value
Indications for ADT, n (%) 0.534a
Locally advanced PCa 211 (59.9) 187 (56.0) NA NA
Relapsing PCa following RP 88 (25.0) 95 (28.4) NA NA
Relapsing PCa following other therapies 53 (15.1) 52 (15.6) NA NA
Time since diagnosis, d, median (range) 74 (0–4401) 88 (0–4185) 43 (0–5470) 66 (0–5470) 0.544b
Prior therapy, n (%)
Any surgery 120 (33.2) 115 (33.8) 35 (15.2) 270 (29.0) 0.870a
Any radiation 60 (16.6) 66 (19.4) 30 (13.0) 156 (16.7) 0.336a
Any chemotherapy 0 3 (0.9) 1 (0.4) 4 (0.4) 0.114c
Any other therapy 56 (15.5) 55 (16.2) 24 (10.4) 135 (14.5) 0.810a
Gleason score, n (%) 0.752a
6 142 (39.7) 127 (37.7) 72 (31.2) 341 (36.8)
7 134 (37.4) 125 (37.1) 85 (36.8) 344 (37.1)
8 82 (22.9) 85 (25.2) 74 (32.0) 241 (26.0)
Missingd 3 3 0 6
T, n (%) 0.082c
T0–2 64 (9.1) 78 (11.7) 25 (5.5) 167 (9.2)
T3–4 284 (40.6) 254 (38.3) 204 (44.5) 742 (40.7)
TX 4 (0.6) 0 0 4 (0.2)
Missingd 9 8 2 19
Comorbidities of interest, n (%)
Hypertension 194 (53.7) 173 (50.9) 118 (51.1) 485 (52.0) 0.449a
Hypercholesterolaemia 47 (13.0) 61 (17.9) 17 (7.4) 125 (13.4) 0.071a
Diabetes mellitus 33 (9.1) 39 (11.5) 17 (7.4) 89 (9.5) 0.310a
Myocardial ischaemia 35 (9.7) 45 (13.2) 36 (15.6) 116 (12.4) 0.141a
ADT = androgen deprivation therapy; CAD = continuous androgen deprivation; IAD = intermittent androgen deprivation; NA = not applicable; PCa = prostate
cancer; RP = radical prostatectomy.
a Chi-square test.
b Log rank test.
c Fisher exact test.
d Missing patients not included in percentage calculations.
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The median number of IAD injections administered during
the randomised phase was 3 (range: 1–10) compared with
12 (range: 1–12) for the CAD group, with amean duration of
327 d and 89 d between injections for the IAD and CAD
groups, respectively. Of patients receiving IAD, 36%, 22%,
and 16% did not need to reinitiate ADT atmonths 12, 24, and
36, respectively. In the IAD group, 184 patients received
13 injections, 76 received 46 injections, 8 received
79 injections, and 5 received 1012 injections.
The mean testosterone level at randomisation was
11.4 ng/dl (0.4 nmol/l) for the IAD group. Mean testosterone
levels subsequently increased (range: 61.0268.0 ng/dl
[2.19.3 nmol/l]), and at 36mo (visit 16)mean testosterone
was 174.3 ng/dl (6 nmol/l).
3.2. Primary end point
Time to PSA progression did not statistically differ between
treatment groups (p = 0.718), with a similar number of
events recorded in each group (34 for CAD and 30 for IAD)
(Fig. 2) at 36 mo. Median time to PSA progression was not
reached. Estimated 3-yr PSA progression rate percentage
was 10.6 (95% confidence interval [CI], 7.714.6) and 10.1
(95% CI, 7.114.2) for CAD and IAD, respectively. Similar
results were observed when the analysis was stratified by
primary diagnosis.3.3. Secondary end points
PSA PFS did not differ significantly (p = 0.865) between the
CAD and IAD groups (43 vs 41 events) (Supplementary Fig.
2); estimated 3-yr PSA PFS percentage was 13.2 (95% CI,
10.017.5) and 13.1 (95% CI, 9.717.5) for CAD and IAD,
respectively. There was a steep decrease in mean PSA levels
by the end of the induction phase in both groups that was
maintained through to visit 16 (Fig. 3).
Overall, 86men died within 5 yr of study entry (44 in the
CAD group and 42 in the IAD group) with no difference in OS
between groups (p = 0.969) (Fig. 4). The estimated 5-yr OS
percentage was 85.0 (95% CI, 80.088.8) and 81.8 (95% CI,
74.787.2) for CAD and IAD, respectively; this difference
was not statistically significant.
Most CAD patients maintained castrate levels of
testosterone throughout treatment (values remained
between 9.0 and 12.9 ng/dl [0.3 and 0.5 nmol/l]), with
breakthrough events occurring in 22 patients (6.3%). Time
to conventional testosterone breakthrough during CAD is
shown in Supplementary Figure 3.
3.4. World Health Organization/Eastern Cooperative Oncology
Group performance status
The patients’ WHO/ECOG status tended to deteriorate
toward the end of the treatment period, with no notable
differences between treatment groups.
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Fig. 3 – (A) Mean prostate-specific antigen levels at each visit; (B) mean (standard deviation) testosterone levels at each visit.
CAD = continuous androgen deprivation; IAD = intermittent androgen deprivation; PSA = prostate-specific antigen.
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CAD = continuous androgen deprivation; IAD = intermittent androgen deprivation; PSA = prostate-specific antigen.
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QoL using EORTC QLQ-C30 was comparable for the IAD
and CAD groups (Supplementary Table 3). For the
functional scales, the mean scores were all >80 with no
notable changes during the randomised phase. Meanglobal health status scores decreased slightly during
the randomised phase, with no notable differences
between groups. Nausea, vomiting, and appetite loss
were the most distressing symptoms reported. Additional
QoL data are reported in Supplement 1 and Supplementary
Table 4.
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Fig. 4 – Kaplan-Meier plots for time to overall survival.
CAD = continuous androgen deprivation; IAD = intermittent androgen deprivation.
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During the randomised phase, 510 patients (73.9%) had one
AE or more, with no clinically relevant difference between
groups (Table 2). Overall, 178 patients (25.8%) had one orTable 2 – Summary of adverse events and treatment-related adverse e
CAD
(n = 352)
Patients with any TEAE, n (%) 256 (72.5)
Patients with TEAE by severity, n (%)
Grade 1: mild 47 (13.3)
Grade 2: moderate 109 (30.9)
Grade 3: severe 73 (20.7)
Grade 4: life threatening/disabling 17 (4.8)
Grade 5: death 9 (2.5)
Missing 1 (0.3)
Patients with treatment-related TEAEsd, n (%) 145 (41.1)
Patients with serious TEAEs, n (%) 88 (24.9)
Patients with treatment-related serious TEAEsd, n (%) 4 (1.1)
Deathsf, n (%) 9 (2.5)
Discontinued due to TEAEg, n (%) 17 (4.8)
Discontinued due to treatment-related TEAEd,g, n (%) 4 (1.1)
AEs of interest, n (%)
Hot ﬂushes 68 (19.3)
Hypertension 45 (12.7)
Constipation 21 (5.9)
Back pain 18 (5.1)
Fatigue 17 (4.8)
AE = adverse event; CAD = continuous androgen deprivation; IAD = intermittent a
a Study population includes patients who were randomised and for whom postr
b Chi-square test.
c One patient died, but the cause of death was not recorded as a grade 5 AE.
d AEs that are possibly or probably treatment related or for which the relationsh
e Fisher exact test.
f Only AEs with outcome ‘‘fatal’’ are counted.
g Only AEs that were the primary reason for discontinuation are taken into accomore serious AEs. The most common AEs were hot flushes,
hypertension, and constipation (Table 2); most were grade 1
(mild) or grade 2 (moderate). Supplementary Table 5 shows
the AEs occurring in 2% of patients during the randomised
phase. Forty-two patients (6.1%) discontinued randomisedvents (randomised phase)a
IAD
(n = 334)
Total
(n = 686)
p value
254 (75.4) 510 (73.9) 0.394b
0.966b
53 (15.7) 100 (14.5)
107 (31.8) 216 (31.3)
63 (18.7) 136 (19.7)
16 (4.7) 33 (4.8)
14 (4.2)c 23 (3.3)
1 (0.3) 2 (0.3)
124 (36.8) 269 (39.0) 0.394b
90 (26.7) 178 (25.8) 0.594b
4 (1.2) 8 (1.2) 1.000e
15 (4.5) 24 (3.5) 0.173b
25 (7.4) 42 (6.1) 0.153b
0 4 (0.6) 0.124e
72 (21.4) 140 (20.3) 0.493b
37 (11.0) 82 (11.9) 0.473b
23 (6.8) 44 (6.4) 0.638b
19 (5.6) 37 (5.4) 0.753b
15 (4.5) 32 (4.6) 0.820b
ndrogen deprivation; TEAE = treatment-emergent adverse event.
andomisation safety data were available.
ip is missing.
unt.
E U RO P E AN URO LOGY 6 9 ( 2 0 1 6 ) 7 2 0 – 7 2 7726treatment due to AEs. Analysis of AEs in patients with locally
advanced versus relapsing PCa at baseline revealed no
differences between CAD and IAD regarding number of AEs,
serious AEs, or AEs leading to drug discontinuation. Twenty-
four patients (3.5%) died during randomised treatment; no
deaths were deemed related to treatment.
4. Discussion
In this largemulticentre randomised study of IAD and CAD in
patientswith relapsingM0after RP or radiotherapy or locally
advanced PCa, there were no statistically significant or
clinically relevant differences between groups for any time-
to-event end points (time to PSA progression, PSA PFS, or OS)
or mean PSA levels over time. Results were seen in the
context of considerably fewer injections in the IAD than CAD
group (median: 3 for IAD and 12 for CAD). However, there
were no apparent differences in performance status, QoL, or
treatment tolerability between groups; both treatment
strategies were similarly well tolerated, and most drug-
related (and non–drug-related) AEs were mild to moderate.
A number of previously published studies have com-
pared CAD and IAD, many in samples of <500 patients
[4,6–9,12–20], but only one phase 3 study has been
conducted in a purely nonmetastatic population [13]. Crook
et al compared IAD with CAD in a large patient group that
previously received primary or salvage radiotherapy for
localised PCa [13]. IAD was found to be noninferior to CAD
with respect to OS (median: 8.8 vs 9.1 yr). All other studies
comparing IAD with CAD included either a mix of patients
withmetastatic and nonmetastatic disease, or only patients
with metastatic disease. Some of these have shown better
QoL or improvement in individual side effects among those
treated with IAD compared with CAD [14,17]. A recent
open-label study assessing IAD with a LHRH antagonist in
213 patients of varying disease stage observed improved
sexual functioning and fewer AEs during the off-treatment
period [21].
Benefits of IAD on sexual functioning and AEs were also
confirmed in a recentmeta-analysis of 13 trials composed of
6419 patients with hormone-sensitive PCa [8]. Although
these findings are generally positive, it has been suggested
that such benefits are at bestmodest andmaydepend on off-
treatment period length and time to recovery of testosterone
levels [7]. Taken together, these studies fail to provide
consistent support for the theoretical IAD benefits, although
they suggest there is no disadvantage to this approach either.
In our study, PSA progression in the CAD arm was
markedly lower thanreported in the studybydeLeval et al on
which our power assumptions were based, although the
small sample size and different population in that study
(n = 33 in the CAD group) could at least partly explain the
difference [12].
IAD requires fewer drug doses, potentially leading to cost
savings [4,22]. Although drug administration costs are likely
to be lower for IAD, it should be noted that this approach
requires strict follow-up monitoring, resulting in costs not
associatedwith CAD thatwould need to be balanced against
any absolute cost reductions from decreased drug use.Strengths of this study are its large sample size, multiple
objective outcome measures, and the exclusively nonmeta-
static disease population. Our study, which adds to the
small number of well-powered comparative studies in this
patient population, is the first industry-sponsored study of
its kind. We recognise that the treatment approach for the
patients in the ICELAND study may have been different if
conducted today; however, at the time of study initiation
(2006), the options presented to patients were in line with
typical practice and accepted guidelines. The primary study
limitations are the open-label design and absence of formal
assessment of testosterone recovery. We also acknowledge
that PSA progression, as used in our study, is not a
recognised surrogate end point for efficacy. It is, however,
a modest end point for objective response and is strongly
associated with OS [23]. Furthermore, the other outcomes
used in the ICELAND study, namely PFS and OS, are of major
clinical interest. Taken together, these end points provide
appropriate data to contribute meaningfully to the knowl-
edge base on IAD versus CAD.
5. Conclusions
In this open-label trial, IAD and CAD administered after a
6-mo induction with leuprorelin acetate 22.5 mg 3-mo
depot demonstrated comparable efficacy, tolerability, and
QoL in patients with nonmetastatic locally advanced or
relapsing PCa. The principal potential benefits of IAD
compared with CAD include reduced drug acquisition costs
with comparable OS rates. There were no apparent
differences in QoL benefits between the treatment groups.
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